Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2): Compliance, Safety, and Effects on Quality of Life

Ítems similars

• Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function
  per: Jeppesen, P. B., et al.
  Publicat: (2009)
• Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon
  per: Jeppesen, P, et al.
  Publicat: (2000)
• Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure
  per: Jeppesen, P, et al.
  Publicat: (1999)
• Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice
  per: Thulesen, J, et al.
  Publicat: (2004)
• Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients
  per: Jeppesen, P B, et al.
  Publicat: (2005)